Hostname: page-component-89b8bd64d-46n74 Total loading time: 0 Render date: 2026-05-06T13:06:40.013Z Has data issue: false hasContentIssue false

Validation and incidence of community-acquired pneumonia in patients with type 2 diabetes in the BIFAP database

Published online by Cambridge University Press:  31 August 2017

L. C. SAIZ
Affiliation:
Unit of Drug Assessment, Advice and Research, Navarre Regional Health Service, Plaza de la Paz s/n, Pamplona, Navarre 31002, Spain
J. GARJÓN
Affiliation:
Unit of Drug Assessment, Advice and Research, Navarre Regional Health Service, Plaza de la Paz s/n, Pamplona, Navarre 31002, Spain
J. GORRICHO
Affiliation:
Planning, Evaluation and Management Service, General Directorate of Health, Government of Navarre, Calle Irunlarrea 3 (Pabellón Docencia del Hospital de Navarra), Pamplona, Navarre 31008, Spain
J. ERVITI
Affiliation:
Unit of Drug Assessment, Advice and Research, Navarre Regional Health Service, Plaza de la Paz s/n, Pamplona, Navarre 31002, Spain
M. J. GIL-GARCÍA
Affiliation:
BIFAP. Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS). Calle Campezo no 1, Edificio 8, Madrid 28022, Spain
E. MARTÍN-MERINO*
Affiliation:
BIFAP. Division of Pharmacoepidemiology and Pharmacovigilance. Spanish Agency of Medicines and Medical Devices (AEMPS). Calle Campezo no 1, Edificio 8, Madrid 28022, Spain
*
*Author for correspondence: E. Martín-Merino, BIFAP, Spanish Agency of Medicines and Medical Devices (AEMPS), C/Campezo no 1, Edificio 8, Madrid 28022, Spain. (Email: emartin_fcsai@bifap.aemps.es)
Rights & Permissions [Opens in a new window]

Summary

Oral anti-diabetic drugs (OADs) have been associated with community-acquired pneumonia (CAP). We aimed to validate the recording of CAP in the Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP) for the future evaluation of OAD–CAP association. The incidence rate (IR/1000 person-years) of CAP in type 2 diabetes mellitus (T2DM) was also determined. In total, 2966 pneumonia records (2040 listed as diagnosis and 926 as identified from comments added by physicians) were identified from 76 009 patients with T2DM after the first OAD in 2002–2013. Data around the CAP date were reviewed: 1803 (60·9%) were classified as ‘probable CAP’ (confirmed by X-ray/laboratory, referral letters or CAP lung site); 589 (19·8%) as ‘no-case’ (486 had other illness, 78 previous CAP, 25 cancer); and 574 (19·4%) as ‘possible CAP’ (441 without confirmatory information, 133 with uncertain diagnosis or uncertain diagnosis date). In total, 74·2% and 31·4% of pneumonia records in the diagnosis and comments, respectively, were ‘probable cases’ (IR: 6·04), which increased to 90·5% and 42·9%, respectively, when the 441 ‘possible cases’ without confirmatory information were included (IR: 7·52). In summary, diagnosis had a high positive predictive value, and adding cases automatically detected from comments decreased that value significantly.

Information

Type
Original Papers
Copyright
Copyright © Cambridge University Press 2017 
Figure 0

Table 1. Type of record searched for community-acquired pneumonia in the Diagnosis File in BIFAP data structure

Figure 1

Fig. 1. Inclusion criteria, follow-up from the onset of oral antidiabetic drug therapy until pneumonia record in patients with type 2 diabetes mellitus and results of validation of CAP cases.

Figure 2

Table 2. PPV for detection of episodes of CAP by type of record of pneumonia in the Diagnosis File

Figure 3

Table 3. PPV for detection of episodes of CAP by type of record in the medical diagnoses of patient's medical record

Figure 4

Fig. 2. Incidence rate of probable cases of CAP per 1000 person-years of follow-up after first oral antidiabetic drug prescription by age and sex recorded in BIFAP between 2002 and 2013.